SUM-44 and SUM-52 are examples of luminal B breast cancer cell lines, the most aggressive form of estrogen receptor positive breast cancer responsible for the largest number of breast cancer deaths. SUM-44 cells express very high levels of ER-alpha, which is constituitively active in these cells
SUM 102, SUM-149, SUM-229, SUM-1315, and SUM-159 are examples of triple negative breast cancer cell lines (TNBC).
SUM-149 and SUM-190 are inflammatory breast cancer cell lines. These are the only two cell lines in existence derived from patients with this aggressive and drug resistant form of breast cancer.
SUM-149 cells are PTEN null and represents the BL2 subclass of triple negative breast cancers, a particularly aggressive and drug resistant type of TNBC. SUM-149 cells have a BRCA1 mutation.
SUM-102 was derived from a patient with extensive ductal carcinoma in situ (DCIS). SUM-225 was also derived from a high grade DCIS specimen and recapitulates that growth pattern in vivo.
SUM-159 is of the claudin low subset of TNBC and is highly enriched for breast cancer stem cells, thus most of the papers with this cell line have to do with breast cancer stem cell biology.
SUM-1315 is spontaneously metastatic and is widely used as a model for metastatic disease. This too is claudin-low basal breast cancer and has a BRCA1 mutation.
SUM-225, SUM-190, SUM-52, and SUM-185 are cell lines with amplification and over expression of driving oncogenes of the Receptor Tyrosine Kinase family:
- SUM-225 and SUM-190 are HER2 amplified
- SUM-52 and SUM-185 have FGFR2 and FGFR3 respectively as driving oncogenes
- SUM-185 is a member of the androgen receptor expressing class of basal breast cancers.
Back to SLKBase Home
